Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02HKC
|
|||
| Former ID |
DIB007100
|
|||
| Drug Name |
MUC1-Poly-ICLC
|
|||
| Synonyms |
Mucin1 peptide vaccine (cancer), University of Pittsburgh
Click to Show/Hide
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Colorectal cancer [ICD-11: 2B91.Z] | Phase 2 | [1] | |
| Company |
University of Pittsburgh
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Mucin-1 (MUC1) | Target Info | . | [2] |
| WikiPathways | Hematopoietic Stem Cell Differentiation | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00773097) Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma. U.S. National Institutes of Health. | |||
| REF 2 | Early in vivo signaling profiles in MUC1-specific CD4+ T cells responding to two different MUC1-targeting vaccines in two different microenvironments. Oncoimmunology. 2013 Mar 1;2(3):e23429. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.